According to Kaineng Health's announcement, the first half of 2026 achieved operating income of 921 million yuan, an increase of 1.47%; net profit attributable to shareholders of listed companies was 404.53 million yuan, a year-on-year decrease of 39.61%; after deducting non-net profit of 25.21.4 million yuan, a year-on-year decrease of 60.25%. The company plans to use 25 million yuan to 50 million yuan to repurchase shares at a repurchase price of no more than 6.5 yuan/share for equity incentives or employee stock ownership plans. During the reporting period, the company completed the acquisition of 100% of the shares of the four subsidiaries of Yuanneng Group and the remaining 5% of Zhejiang Kaineng Runxin's shares, received US tariff rebates affecting net profit of 10.636,900 yuan corresponding to the mother, and completed a board change.

According to Kaineng Health's announcement, the first half of 2026 achieved operating income of 921 million yuan, an increase of 1.47%; net profit attributable to shareholders of listed companies was 404.53 million yuan, a year-on-year decrease of 39.61%; after deducting non-net profit of 25.21.4 million yuan, a year-on-year decrease of 60.25%. The company plans to use 25 million yuan to 50 million yuan to repurchase shares at a repurchase price of no more than 6.5 yuan/share for equity incentives or employee stock ownership plans. During the reporting period, the company completed the acquisition of 100% of the shares of the four subsidiaries of Yuanneng Group and the remaining 5% of Zhejiang Kaineng Runxin's shares, received US tariff rebates affecting net profit of 10.636,900 yuan corresponding to the mother, and completed a board change.